# Galera Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Galera Therapeutics, Inc.). ## Overview Galera Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing therapies for difficult-to-treat breast cancers. After acquiring Nova Pharmaceuticals in late 2024, the company shifted its strategy toward a pan-NOS inhibitor program and retained two SOD mimetic assets from its earlier portfolio. ## Products & services • Pan-NOS inhibitor for advanced breast cancer • Phase 1/2 combination trial in metaplastic breast cancer (MpBC) • Planned TNBC study with the I-SPY 2 consortium • Avasopasem supply for investigator-sponsored HR+ breast cancer trial • Small-molecule SOD mimetic oncology programs - **Pan-NOS inhibitor program** (45%) — Clinical-stage nitric oxide synthase inhibitor being developed for advanced breast cancer indications. - **SOD mimetic oncology assets** (35%) — Legacy small-molecule dismutase mimetics, including avasopasem, supported mainly through clinical supply commitments. - **Clinical development services** (20%) — Company-run and investigator-sponsored trial support, including drug supply, protocol support and development oversight. - Pan-NOS inhibitor for metaplastic breast cancer and refractory TNBC - Phase 1/2 combination trial with nab-paclitaxel and alpelisib - Planned TNBC trial in collaboration with the I-SPY 2 consortium - Avasopasem drug supply for HR+ breast cancer investigator study - Two clinical-stage SOD mimetics from the legacy portfolio ## Customers Galera does not sell commercial products today; its primary counterparties are clinical investigators, research hospitals, and consortium partners running oncology trials. Future customers, if development succeeds, would be oncology specialists and cancer centers treating advanced breast cancer patients. The company also relies on grant-funded academic collaborators and contract research organizations to execute studies. - **Investigator-sponsored trial sites** (primary) — Academic hospitals and investigators receive drug supply and study support for NIH-funded breast cancer trials. - **Clinical research consortia** (primary) — Collaborative networks such as I-SPY 2 help test the pan-NOS inhibitor in broader TNBC populations. - **Oncology treatment centers** (secondary) — Cancer centers are the eventual end users if the company secures regulatory approval and commercialization. - **Contract research and manufacturing partners** (primary) — CROs, CMOs and consultants are paid to run studies, manufacture materials and support development. - Academic investigators running NIH-funded breast cancer trials - Hospitals and cancer centers enrolling MpBC and TNBC patients - Consortium partners such as I-SPY 2 for multi-site development - CROs, CMOs and consultants supporting preclinical and clinical work - Future oncology prescribers if a candidate reaches approval ## Geography Galera is headquartered in the United States and its development activity is centered on U.S. clinical sites, including Houston Methodist in Texas. The company’s current footprint is therefore concentrated in U.S.-based research and trial execution rather than commercial sales. Its OTCQB listing also keeps the company tied to U.S. capital markets for funding. - Headquartered in the United States - Clinical trial activity centered in Houston, Texas - U.S.-based NIH-funded investigator studies - OTCQB listing in the U.S. capital markets - No disclosed commercial geography because the company is pre-revenue ## Strategy The company’s strategy changed materially after the Nova acquisition, with a new focus on advanced breast cancer programs built around a pan-NOS inhibitor. Near term, Galera is prioritizing clinical readouts, investigator-sponsored studies, and low-cash-burn development supported by grants and existing drug supply. The goal is to preserve capital while advancing proof-of-concept data that could support partnering or future financing. - **Advance the pan-NOS inhibitor in MpBC** (short-term) — This is the lead asset and the main source of future value creation. - **Expand development into TNBC** (medium-term) — Broader TNBC activity could enlarge the addressable patient population and improve partnering appeal. - **Maintain capital efficiency** (short-term) — The company has limited cash and needs to extend runway while advancing clinical milestones. - Advance the lead pan-NOS inhibitor in MpBC - Use NIH-funded investigator-sponsored trials to reduce cash burn - Expand into TNBC through the I-SPY 2 collaboration - Support avasopasem studies with existing supply inventory - Preserve runway through 2026 and reach data readout - Position the portfolio for partnering or follow-on financing ## Risks Galera remains a high-risk clinical-stage biotech with no commercial revenue and a heavy dependence on successful trial execution, regulatory outcomes and future financing. The company also faces going-concern and dilution risk because its cash resources are limited and development programs are still early. As with other oncology developers, clinical failure, safety issues, enrollment delays and partner dependence can materially impair value. - **Clinical development failure** [critical] — The company’s value depends on positive results from early-stage oncology trials. - **Going-concern and financing risk** [high] — Cash resources are limited and the company may need additional capital before commercialization. - **Regulatory and trial execution risk** [high] — Enrollment, protocol changes, safety findings and regulatory requirements can delay or derail studies. - **Dependence on external collaborators** [medium] — Key studies rely on NIH grants, investigators and consortium partners rather than fully internal execution. - No approved products or commercial revenue - Clinical trial failure could eliminate the lead asset's value - Limited cash creates going-concern and financing risk - Safety or efficacy issues could stop development - Dependence on NIH grants and investigator-sponsored studies - OTC listing may limit liquidity and financing flexibility ## Accounting Galera’s accounting is dominated by R&D expense recognition, fair-value judgments and estimates tied to a development-stage biotech structure. Because the company has no product revenue, operating results are driven by clinical spending, share-based compensation and any non-cash valuation items rather than sales recognition. Investors should also watch going-concern disclosures, cash runway assumptions and any impairment or contingent liability judgments related to the portfolio transition. - **Research and development expense recognition** — Quarterly volatility in operating expense and net loss - **Going-concern assessment** — Important for liquidity disclosure and financing risk - **Share-based compensation** — Affects both R&D and G&A expense - **Acquisition and asset valuation** — Could affect intangible asset carrying values and future impairment risk - R&D costs are expensed as incurred, driving large operating losses - Clinical trial and CRO/CMO spend can be uneven quarter to quarter - Share-based compensation affects G&A and R&D expense - Going-concern assessment depends on cash runway assumptions - Acquisition-related valuation and impairment judgments may arise --- *Last updated: 2026-04-28T20:10:58.132697+00:00*